Geoffrey R. Erickson
Fondateur chez Immunis.AI, Inc.
Profil
Dr. Geoffrey R.
Erickson is a Director-Business Development at Office of Technology Development.
Prior to joining OTD in 2009, he was CEO of Humacyte, Inc., a company created from technology out of Duke University and MIT.
Prior to his role at Humacyte, Dr. Erickson was a venture capitalist with Pappas Ventures, a firm focused on investments in the life science industry which he joined in 2001.
In addition, he worked with Pappas Ventures as a co-founder of CoLucid Pharmaceuticals.
Dr. Erickson received a BSE in engineering from Duke University, an MSE in engineering from Tulane University, and a PhD in biomedical engineering from Duke University.
Postes actifs de Geoffrey R. Erickson
| Sociétés | Poste | Début |
|---|---|---|
Immunis.AI, Inc.
 Immunis.AI, Inc. Packaged SoftwareTechnology Services Immunis.AI, Inc. develops a non-invasive blood-based immunogenomic platform. The company is based in Royal Oak, MI. The company was founded by Geoffrey R. Erickson, Harry Stylli, Amin I. Kassis. | Fondateur | - |
Anciens postes connus de Geoffrey R. Erickson
| Sociétés | Poste | Fin |
|---|---|---|
Humacyte Global, Inc.
 Humacyte Global, Inc. Medical SpecialtiesHealth Technology Humacyte Global, Inc. engages in the manufacture of human acellular matrix products for vascular and non-vascular applications. It offers its products to the cardiovascular, cosmetic, soft tissue reconstruction, neurosurgical, and orthopedic markets. The company was founded by Laura E. Niklason, Juliana L. Blum and Shannon L. M. Dahl in 2004 and is headquartered in Durham, NC. | President | 31/12/2008 |
Pappas Capital LLC
 Pappas Capital LLC Investment ManagersFinance Pappas Capital LLC (Pappas Ventures) is a venture capital firm founded in 1994 by Art M. Pappas. The firm is headquartered in Durham, North Carolina. | Analyste en capital-investissement | 31/12/2007 |
Office of Technology Development
 Office of Technology Development Investment ManagersFinance Office of Technology Development (Office of Technology Development) is a venture capital subsidiary of Harvard University founded in 2007. The firm is headquartered in Cambridge, Massachusetts. | Corporate Officer/Principal | - |
Formation de Geoffrey R. Erickson
| Duke University | Doctorate Degree |
| Tulane University (Louisiana) | Graduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Humacyte Global, Inc.
Humacyte Global, Inc. Medical SpecialtiesHealth Technology Humacyte Global, Inc. engages in the manufacture of human acellular matrix products for vascular and non-vascular applications. It offers its products to the cardiovascular, cosmetic, soft tissue reconstruction, neurosurgical, and orthopedic markets. The company was founded by Laura E. Niklason, Juliana L. Blum and Shannon L. M. Dahl in 2004 and is headquartered in Durham, NC. | Health Technology |
Pappas Capital LLC
Pappas Capital LLC Investment ManagersFinance Pappas Capital LLC (Pappas Ventures) is a venture capital firm founded in 1994 by Art M. Pappas. The firm is headquartered in Durham, North Carolina. | Finance |
Office of Technology Development
Office of Technology Development Investment ManagersFinance Office of Technology Development (Office of Technology Development) is a venture capital subsidiary of Harvard University founded in 2007. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Immunis.AI, Inc.
Immunis.AI, Inc. Packaged SoftwareTechnology Services Immunis.AI, Inc. develops a non-invasive blood-based immunogenomic platform. The company is based in Royal Oak, MI. The company was founded by Geoffrey R. Erickson, Harry Stylli, Amin I. Kassis. | Technology Services |